CRISPR Therapeutics Reveals Innovative Data at AHA 2025 Event
CRISPR Therapeutics Shows Groundbreaking Results at AHA 2025
CRISPR Therapeutics, a pioneering biopharmaceutical firm known for its innovative gene-editing solutions, has announced an exciting opportunity. During the upcoming American Heart Association (AHA) Scientific Sessions 2025, the company will present crucial findings from its Phase 1 clinical trial. This trial investigates the efficacy of CRISPR/Cas9 technology in addressing cardiovascular conditions.
Insights on CRISPR/Cas9 Gene Editing Therapy
The spotlight will be on CTX310™, an experimental gene therapy aimed at targeting angiopoietin-related protein 3 (ANGPTL3). This treatment is designed for combating cardiovascular and cardiometabolic diseases. The oral presentation will occur on November 8, 2025, at 8:30 a.m. CST, featuring an in-depth review of the trial results.
Focus on Another Key Therapy: CTX340™
Additionally, CRISPR Therapeutics will showcase CTX340™, which targets angiotensinogen (AGT) to address refractory hypertension. A poster presentation highlighting the preclinical program will be presented later that same day, providing further insights into the potential of gene editing in hypertension treatment strategies.
Important Session Details
Here are some key details regarding the presentations:
Abstract Title: First-in-Human Phase 1 Clinical Trial of a CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3
Abstract Number: 4392851
Session Type: Late-Breaking Science (Oral Presentation)
Session Title: Groundbreaking Trials in Cardiometabolic Therapeutics
Session Date and Time: Saturday, November 8, 2025, 8:30 a.m. CST
Abstract Title: In vivo gene editing of Angiotensinogen in hepatocytes safely and potently reduces blood pressure in preclinical models
Abstract Number: 4391815
Session Type: Late-Breaking Basic Science (Poster Presentation)
Session Title: Precision Interventions for the Failing Heart: Genetic, Metabolic, and Immune Frontiers
Session Date and Time: Saturday, November 8, 2025, 2:30 p.m. CST
The Latest on CRISPR Therapeutics’ Advancements
CRISPR Therapeutics continues to strengthen its innovative portfolio. This biopharmaceutical company has enhanced its lipid nanoparticle (LNP) platform, enabling the efficient delivery of CRISPR/Cas9 therapies to the liver, which is crucial for treating cardiovascular issues. The lead programs, CTX310 and CTX320, are making progress in clinical trials focusing on familial hypercholesterolemia and related disorders.
Moreover, the company's R&D initiatives are not limited to CTX310 and CTX320. Other promising candidates include CTX340 and CTX450, which are being explored for their potential in targeting AGT for hypertension management and ALAS1 for acute hepatic porphyria, respectively. These programs signify the commitment CRISPR Therapeutics has toward pioneering treatments for serious ailments.
Milestones Achieved by CRISPR Therapeutics
Over the past decade, CRISPR Therapeutics has risen to prominence within the biotechnology sector. Its trajectory changed dramatically with the approval of the first-ever CRISPR-based therapy. The success of this innovative approach has opened doors for further exploration into genetic therapies aimed at treating a range of disorders like hemoglobinopathies, oncology, and autoimmune diseases.
The advancements underscore the company's dedication to delivering novel therapies that leverage groundbreaking CRISPR technology. As science continues to evolve, CRISPR Therapeutics remains committed to making strides towards effective solutions for complex medical challenges.
Contact Information for Investor and Media Inquiries
For those interested in learning more about CRISPR Therapeutics and its ongoing projects, the company provides dedicated contact resources:
Investor Contact:
+1-617-307-7503
ir@crisprtx.com
Media Contact:
+1-617-315-4493
media@crisprtx.com
Frequently Asked Questions
What is CRISPR Therapeutics focusing on at the AHA 2025?
CRISPR Therapeutics will present findings related to its Phase 1 clinical data for gene editing therapies addressing cardiovascular diseases.
What are CTX310 and CTX340?
CTX310 targets ANGPTL3 for heart diseases, while CTX340 focuses on reducing blood pressure by targeting angiotensinogen (AGT).
When will the presentations occur?
The oral presentation is scheduled for November 8, 2025, at 8:30 a.m. CST, followed by a poster presentation later the same day.
How long has CRISPR Therapeutics been in operation?
Founded over a decade ago, CRISPR Therapeutics specializes in developing CRISPR-based genetic therapies.
How can I contact CRISPR Therapeutics for inquiries?
Investors can reach out via +1-617-307-7503 or ir@crisprtx.com for investment-related questions.
About The Author
Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.